Skip to main content

Day: February 7, 2022

Triumph Bancorp Announces $50 Million Stock Repurchase Program

DALLAS, Feb. 07, 2022 (GLOBE NEWSWIRE) — Triumph Bancorp, Inc. (Nasdaq: TBK) (“Triumph” or the “Company”) announced today that its board of directors has authorized the Company to repurchase up to $50 million of its outstanding common stock. The Company may repurchase shares from time to time in open market transactions or through privately negotiated transactions at the Company’s discretion. The amount, timing and nature of any share repurchases will be based on a variety of factors, including the trading price of the Company’s common stock, applicable securities laws restrictions, regulatory limitations and market and economic factors. The repurchase program is authorized for a period of up to one year and does not require the Company to repurchase any specific number of shares. The repurchase program may be modified, suspended...

Continue reading

BIO-key’s PortalGuard Identity and Access Control Platform Adds New Mexico’s Rio Arriba County to Growing List of County Government Customers Throughout the US

BIO-key’s PIV-Pro fingerprint readers selected for office users and WEB-key’s MobileAuth with PalmPositive Application for remote users WALL, N.J., Feb. 07, 2022 (GLOBE NEWSWIRE) — BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB), today announced in partnership with iT1 that Rio Arriba County, NM has selected its PortalGuard IAM platform, including WEB-key biometric authentication, to deliver cost-effective, modern security controls for access to all its enterprise resources and mission-critical applications. The County also chose BIO-key’s PIV-Pro fingerprint readers, a highly accurate FIPS 201 compliant scanner for its office users, and remote users will use WEB-key’s MobileAuth...

Continue reading

Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2021 Total Revenues; Provides 2022 Total Revenue Guidance and Corporate Update

2021 Total Revenues Estimated at $141 Million, Representing 18% YoY Growth Forecast 2022 Total Revenues of Between $195 Million and $205 Million, Representing YoY Growth of 38% to 45% Recently Regained Orphan Drug Exclusivity in the U.S. for Amifampridine to Treat LEMS Entering 2022 with a Strong Cash Position of Approximately $191 Million and No Funded Debt Poised to Acquire Products, Pipeline and/or Companies in 2022 CORAL GABLES, Fla., Feb. 07, 2022 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today provided preliminary 2021 fourth quarter and full year total revenue estimates, a forecast of 2022 total revenue...

Continue reading

Graphex Group, a Global Supplier of Graphite, Announces Plans to Establish a Michigan-based EV Battery Materials Production Facility

Graphex Group’s exclusive MOU with Emerald Energy Solutions LLC is a key step toward the construction of a graphite processing facility in the greater Michigan area to support EV battery production across the United States ROYAL OAK, Mich., Feb. 07, 2022 (GLOBE NEWSWIRE) — Graphex Technologies, LLC, a wholly owned subsidiary of Graphex Group Limited (collectively “Graphex”) (OTCQX: GRFXY | HKSE: 6128), has entered into an exclusive non-binding memorandum of understanding (MOU) to form a joint venture with Michigan-based Emerald Energy Solutions LLC (“EES”) for constructing and operating a graphite processing facility. The joint venture is considering several Michigan sites as well as other sites for the facility. Final decision and site selection is expected in March and is subject to agreements being reached with state and local...

Continue reading

Global Pulse Oximeters Market Size [2022-2025] | to Reach USD 2,657.6 Million, at a CAGR 6.7%

Pulse Oximeters Market is projected to grow USD 2,657.6 Million in 2025 at a CAGR of 6.7% during the 2022-2025 period Pune, India, Feb. 07, 2022 (GLOBE NEWSWIRE) — The global pulse oximeters market is likely to grow in the coming years due to increasing usage clearances from the Food and Drug Administration (FDA). According to a report published by Fortune Business Insights, titled “Pulse Oximeters: Global Market Analysis, Insights and Forecast, 2018-2025,” the market is likely to reach US$ 2,657.6 Mn by the end of 2025. Fortune Business Insights states that the market was valued at US$ 1,587.3 Mn in 2017 and will exhibit a CAGR of 6.7% in the forecast period. In the report, Fortune Business Insights has profiled a few companies that are operating in the global pulse oximeter market. Some of the leading companies that have been...

Continue reading

Global Hormone Replacement Therapy Market Size [2022-2028] | to Reach USD 14.17 Billion, at a CAGR 6.1%

Hormone Replacement Therapy Market projected to grow from USD 14.17 billion in 2021 to USD 21.49 billion in 2028 at a CAGR of 6.1% in the 2022-2028 period. Pune, India, Feb. 07, 2022 (GLOBE NEWSWIRE) — The global hormone replacement therapy market size was USD 13.40 billion in 2020. The market is projected to grow from USD 14.17 billion in 2021 to USD 21.49 billion in 2028 at a CAGR of 6.1% in the 2022-2028 period. This information is provided by Fortune Business Insights, in its report titled, “Hormone Replacement Therapy Market, 2022-2028.” According to our expert analysts, the market is witnessing growth, owing to its development in several other hormone-associated illnesses concerned with diverse age groups that are impacting both, women as well as men. Industry Developments: May 2021: Myovant Sciences GmbH declared that it...

Continue reading

Blue Star Foods Corp. to Present at Aegis Virtual Conference

Miami, Florida, Feb. 07, 2022 (GLOBE NEWSWIRE) — Blue Star Foods Corp., (NASDAQ: BSFC) (“Blue Star” or “BSFC”), an integrated Environmental, Social, and Governance (ESG) seafood company, announced today that, John Keeler, CEO of Blue Star Foods will be presenting at the Aegis Virtual Conference which is taking place for three days, February 23, 2022 until February 25, 2022, from 8:30AM until 5PM EST. See details below about Blue Star Food’s presentation: Event: Aegis Capital Virtual Conference Location: Virtual Date: Friday, February 23, 2022 Time: 1:00 p.m. – 1:30 p.m. ET (Presentation and Q&A) To access the event, please download and import the following iCalendar (.ics) files to your calendar system: Aegis Virtual Conference Calendar About Blue Star Foods Corp. Blue Star Foods Corp. is an integrated ESG seafood company...

Continue reading

BioRestorative Therapies to Ring Nasdaq Stock Market Closing Bell

MELVILLE, N.Y., Feb. 07, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical-stage company focused on stem cell-based therapies, today announced that Lance Alstodt, BioRestorative’s Chairman and CEO, along with Francisco Silva, Vice President of Research and Development, have been invited to ring the closing bell at Nasdaq’s stock market closing on Monday, February 7th at 4:00 PM ET in celebration of BioRestoriative’s uplisting to Nasdaq. The ceremony will begin at approximately 3:45PM ET and can be viewed live at https://livestream.com/accounts/27896496/events/9988418 . “We are honored to ring the closing bell in celebration of our recent uplisting. Our goal is to validate our technology through the regulatory process positioning the Company as a leader in...

Continue reading

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results on March 1, 2022

CANTON, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that fourth quarter and fiscal year 2021 financial results will be reported after the market closes on Tuesday, March 1st. Management will host a conference call at 5:00 p.m. Eastern Time on March 1st to discuss the results of the quarter and fiscal year, and provide a corporate update with a question and answer session. Those who would like to participate may dial 866-795-3142 (409-937-8908 for international callers) and provide access code 5998131. A live webcast of the call will also be provided on the investor relations section...

Continue reading

MariMed Top-Selling Brands and Products Now Available in Delaware

NORWOOD, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) — MariMed, Inc. (OTCQX: MRMD) (“MariMed” or the “Company”), a leading multi-state cannabis operator focused on improving lives every day, today announced that its award-winning cannabis brands and products are now available in Delaware. As a result of new regulations in the Delaware Medical Marijuana program, MariMed has expanded its licensing agreement with First State Compassion Center (“FSC”), a leading Delaware vertically integrated cannabis operator, to produce and distribute its branded cannabis edibles. First State Compassion will have exclusive rights to produce and distribute MariMed’s Betty’s Eddies® infused fruit chews, Bubby’s Baked™ soft and chewy, full-spectrum cannabis baked bites, and k FUSION chewable micro-dose mints. MariMed and FSC have a longstanding advisory relationship....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.